Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T21:28:40.070Z.
Calculation as of: 2026-10-06T21:28:40.070Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 09a0ab09da9db255713b3d52bc1d4f6ff3c974c87d2899d50b33d975ee1631b8
PEG RATIO
N/A
Prelude Therapeutics Incorporated
Market Cap
$216.91M
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| Prelude Therapeutics Incorporated (PRLD) | $216.91M | N/A |
| Keros Therapeutics, Inc. (KROS)vs › | $218.30M | N/A |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $215.07M | N/A |
| Sionna Therapeutics, Inc. (SION)vs › | $214.46M | N/A |
| Niagen Bioscience Inc (NAGE)vs › | $214.24M | N/A |
| Profound Medical Corp. (PROF)vs › | $220.93M | N/A |
| Lyell Immunopharma, Inc. (LYEL)vs › | $210.98M | N/A |
| Entrada Therapeutics, Inc. (TRDA)vs › | $210.41M | N/A |
| Compugen Ltd. (CGEN)vs › | $209.91M | N/A |
| Nautilus Biotechnolgy, Inc. (NAUT)vs › | $225.24M | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
